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Introduction
The concept of Neglected Tropical Diseases (NTDs) emerged more than a decade ago and has been recognised as a valid categorisation of diseases of the poorest. Significant progress in control or elimination has been achieved and policy momentum generated through continued bilateral, philanthropic and NGDO support and donations of NTD drugs from pharmaceutical companies. WHO has defined a Road Map to reach 2020 targets endorsed by member states in a World Health Assembly Resolution in 2013. NTDs have been included within the Sustainable Development Goal targets and are a critical component of Universal Health Coverage conceptualised as “leaving no one behind”. WHO reported that, in 2014, over one billion people in 88 countries have benefited from Preventive Chemotherapy. The research agenda is well defined-, the need for affordable products- diagnostics, drugs and insecticides, whilst challenges such as insecurity and weak health systems continue to prevail in the poorest countries inhibiting progress in scaling up and also achieving Roadmap goals. 

Background and history of NTDs: the WHO Roadmap, the London Declaration: NTD and the Global Heath agenda

This paper reviews progress since a Lancet Series on neglected tropical diseases (NTDs) was published in 2010.1-4  NTDs have been defined as a group of infections strongly associated with poverty in tropical and sub tropical environments. They are diverse biologically and in transmission characteristics predominantly infecting populations in low and middle-income countries with limited access to health services.5 Over the last decade the momentum to address NTDs has been driven by the pledges of pharmaceutical companies to provide free medicines-all on the WHO Essential Medicines list and valued in billions of US$, the Non-Governmental Development Organizations’ (NGDO) commitments to assist implementation of programmes in endemic countries, the bilateral support from the US and UK governments and an increase in commitment from endemic countries.6 However,  despite evidence that interventions to address NTDs are one of the best health investments only 0.6% of Official Development Assistance for Health is provided to NTDs which affect over one billion people  reflecting a persistent and continuing inequity in global health financing.7 

The London Declaration of 2012 recorded increased commitments of donated drugs for visceral leishmaniasis, lymphatic filariasis and schistosomiasis whilst reinforcing earlier commitments to provide drugs for fascioliasis, leprosy, leishmaniasis, lymphatic filariasis, onchocerciasis, trypanosomiases, and soil-transmitted helminthiases at no cost to endemic countries.8 In 2013, the World Health Assembly approved Resolution WHA 66.12 which defined strategies for NTDs with clear targets and milestones on 17 NTDs and endorsed the WHO NTD Roadmap goals linking NTDs to Universal Health Coverage. The NTDs are addressed through five strategies: preventive chemotherapy, intensified disease management, vector control, zoonotic neglected diseases and through improved water and sanitation.9-10

The momentum for further investment came in 2015 with the inclusion of NTDs within the health targets of the Sustainable Development Goals (SDGs)11 when the Global Fund Board12 agreed to support interventions which addressed co-infection and co-morbidities and the G7 Heads of State in 2015 recognised NTDs as a major challenge emphasising the need to support research and interventions.13 An agreed SDG target was that there is a 90% reduction in those numbers of people requiring preventionaccessing  against NTDs interventions by 2030. However, a heavy burden of NTDs is found in the poorest segments of the population of G20 countries (together with Nigeria) and if G20 countries would implement NTD programmes a high proportion of the NTD burden could be resolved.14

Increased investment will improve the well-being of vulnerable groups, women and children which together with water, sanitation, hygiene and education benefits are all appropriate links to many of the SDGs. NTDs define poverty in many settings and have been described as a “litmus test” of progress in poverty alleviation - markers of poverty.15

NTD partnerships: Evolution and expansion - from disease-specific to a wider context 

Disease specific partnerships represent the diversity of communities involved in NTDs and have made a major contribution to the upscaling of programmes. NGDO commitment was pioneered by NGDOs who supported the delivery of ivermectin for onchocerciasis control and leprosy elimination programmes.16 Since 2010 new partnerships have emerged to coordinate and advocate for particular conditions (See Table 1). Disease specific alliances generate opportunities for advocacy and increased resources from non-traditional donors and reflect the need to facilitate interaction between endemic countries, international organizations, NGDOs, pharmaceutical donors, philanthropic foundations and academia. 

Science underpinning the NTD case

 The Burden of NTDs- what is the reality?
The Global Burden of Disease (GBD) study of 201017 attributed some 27 million DALYs to NTDs but a later estimate included other conditions not included within the WHO “official NTD” list of 17 diseases which attributed 47.9 million DALYs to all NTDs18 although an earlier study estimated the burden for NTDs as 56 million DALYs.5 The global annual mortality from NTDs was reported as circa 150,000 deaths per year.17 However, this estimate excluded deaths from rabies (60,000), snake bite (up to 94,000), cancers associated with trematode infections -60,000 deaths and neurological NTD conditions such as neurocysticercosis related epilepsy (60,000) these deaths being included in other categories. These figures suggest the total annual mortality from NTDs is circa 350,000. In 2010, the WHO reported that schistosomiasis mortality alone could be as high as 280,000 per year in Africa- a 20-fold difference from the official GBD data.19 Morbidity from permanent blindness, debilitating skin disease, disability and disfigurement with long term psychological and social and economic consequences will elevate the total DALY burden but are not included in GBD DALY metrics.20 

NTD co-morbidities; HIV, epilepsy and cancers
Recently, a possible relationship between HIV and urogenital schistosomiasis has been recognised. Studies show an increased HIV positivity in females infected with S. haematobium.21 The opportunity to reduce the risk of HIV in young females caused by S. haematobium urogenital pathology by annual praziquantel has yet to be recognized by the HIV community. This is despite the need to achieve high coverage of this at-risk group irrespective of a direct link to HIV. Recently the safety of praziquantel has been reconfirmed during pregnancy and lactation.22 It is important that the longstanding policy to assure coverage of this group with praziquantel treatment is implemented by both the NTD and HIV constituencies. Neurocysticercosis (NCC) infection caused by cysts Taenia solium has been associated with epilepsy and estimates suggest some 30% of global epilepsy is associated with NCC.23 Bladder cancer associated with S. haematobium and food borne trematode infections cause cholioangiocarcinoma estimated to cause some 60,000 deaths annually.24 The successful schistosomiasis control programme in Egypt has seen a rapid decline in bladder cancer over the last two decades.25 Co-morbidities associated with hookworm and schistosomiasis also exacerbate malaria pathology particularly in pregnancy reducing birth weight with increased risk of neonatal and infant mortality. Further, the mental health co-morbidity of many NTDs and the impact these conditions have on the psycho-social status of individuals and families, particularly depressive illness and anxiety of patients and caregivers with NTDs has only recently been highlighted as a problem withcausing significant additional burden.20   Such examples, underline the co-morbidity of NTDs which need to be considered in the estimates of disease burden. 

Definition of Research Priorities
Research priorities for NTDs have been published in a series of WHO/ TDR reports outlining the priorities for the kinetoplastid parasites-trypanosomes and leishmanias, helminth infections, zoonoses and viral infections-dengue and other arboviruses.26 There is a consensus that new drugs, insecticides and diagnostics are required which will offer improved and cost effective therapies, vector control tools and diagnostics. Attempts to develop vaccines for multicellular parasites are yet to develop a product for large-scale use. However, a vaccine for dengue (Dengaxia) which has been licenced in Mexico following safety and efficacy studies in clinical trials for use in highly endemic areas in 9-45 year olds with a prevalence of over 60% representing progress in addressing the expanding dengue threat.27

There is, however, recognition that research directed at improving delivery of existing products and evaluating efficacy of existing therapeutics is necessary allied to the exploration of combinations of products known to be effective. Specific research priorities are for improved oral therapy for Human African Trypanosomiasis effective in both early and late stage disease, for improved chemotherapy of the leishmaniases, Chagas’ Disease and Buruli Ulcer as current therapies fall short of ideal because of the duration of required treatment, mode of administration and toxicity. There remains a need for a short duration macrofilaricidal treatment to kill or permanently sterilise adult filarial worms, as despite the efficacy of the anti-Wolbachia antibiotic, doxycycline, the duration of treatment and the eligibility criteria currently restrict its widespread use. Praziquantel, now donated for schistosomiasis, however requires to be formulated for paediatric use given children lower thean school age is are frequently infected. at a young age. The combination of Praziquantel with artesunate for treating both adults and juvenile forms of schistosomes might be considered.28

Research linked to implementation of programmes and the challenges which programmes face as they mature require social science involvement to improve coverage and adherence and improved methodologies to evaluate impact to address problems identified of acceptability, adherence and coverage.29 A new approach to this is the detailed understanding of the interactions of social networks within communities to ensure optimum understanding and uptake of drugs.30 The increasing complexity and diversity of research questions emerge as programmes dependent on MDA progress related to the duration of the MDA for different diseases, the frequency of MDA, the impact impact,where appropriate of vector control and the broad spectrum impact of the anthelminthics used.31       

Mapping disease distribution
The accurate mapping of distribution of a disease is a pre-requisite for effective implementation. The importance of defining endemicity has been demonstrated in onchocerciasis programmes where levels of endemicity were defined by rapid epidemiological assessment and mapping (REMO).32  Whilst the serious adverse events (SAEs) associated with L. loa co-endemicity required a rapid mapping methodology to define areas of highest risk.33   Similar rapid mapping using antigen detection methods are used to map where LF implementation should be instituted.34 The need to know the distribution of NTDs that can be controlled or eliminated by preventive chemotherapy (PC NTDs) has led to the development of on line resources to ensure all requisite data is available and updated.35 The Global Trachoma Mapping Project (GTMP) is an example of how mobile phone/GIS technologies can be used through population based prevalence surveys in all districts where trachoma is suspected to acquire data on burden and risk enabling prioritization of interventions and defining strategy for implementation of the SAFE strategy.36 The detailed mapping of foci of Human African Trypanosomiasis due to T.b. gambiense has also defined areas of highest risk for active surveillance.37

The use of remote sensing technologies to define more precisely zones of climate (rainfall indices, cloud cover), physical parameters (altitude, soil type) and ecological (forest cover, vegetation type) data sets are increasingly important as predictors of disease ecology reflecting transmission of vector borne infections or are driven by definable physical characteristics such as soil type associated with podoconiosis.38 The NTD global mapping tool provides an interactive means to assist the planning and implementation of PC NTDs,35 enabling visualization of geographic distribution of diseases, the priority areas requiring mass drug administration (MDA), where co-implementation should be initiated, to provide information on water and sanitation and track progress in interventions and complements the Global Atlas of Helminth Infections  www.thiswormyworld.org (​http:​/​​/​www.thiswormyworld.org​)).39 

The need for alternative strategies to hasten achievement elimination targets -the operational research agenda

Some preventive chemotherapy programmes require alternative strategies to reach elimination targets which need to be piloted and implemented. In particular, two times per year ivermectin for onchocerciasis in Africa; treating with albendazole twice a year in onchocerciasis/ Loa loa co-endemic areas together with bednet coverage to achieve elimination of lymphatic filariasis; the use of doxycycline as a macrofilaricide in some areas of onchocerciasis endemicity such as in the Brazil/Venezuela focus or four-times/year ivermectin.31,40 Recent studies of a triple combination of DEC, albendazole and ivermectin have shown that microfilaria levels remain suppressed for a 24 month period thus providing an opportunity to reduce the frequency of MDA in areas where onchocerciasis is not co-endemic.41 In addition to reduce the problem of the limited impact of albendazole on Trichuris infections ivermectin should be considered; however, ivermectin is not donated for this indication or for scabies. The value of bednets to eliminate W. bancrofti transmission needs to be promoted in Africa, recognizing that extensive insecticide resistance exists.42

Cochrane Systematic reviews-the deworming debate 
Recent studies by the Cochrane Collaboration have been published which challenges the benefits of deworming for the control of STH following analysis of randomised control trials (RCTs). This has provoked robust debate43-44 about the appropriateness of RCTs for measuring the nutritional and educational benefits of preventive anthelminthic chemotherapy. Most RCTs do not take into account that recovery from nutritional deficits is a process that takes much longer than one year, especially if the quality and quantity of the nutrients assumed with diet are limited. 
 
Furthermore, a significant proportion of individuals treated with PC are uninfected but are nevertheless treated for logistical reasons given no nutritional benefits are expected to accrue in this group. RCTs normally calculate the mean benefit of PC on the entire treated group but the true benefits are obtained only by those infected and hence in this way, significantly diluted.  
 
In addition, different worm species have different pathological effects: hookworm causing anaemia, ascariasis retarding growth,45 hence when evaluating the results of PC it is important to recognize which are the species of STH removed; for example, an improvement in haemoglobin levels should not be expected if hookworms are not the prevalent species in the population treated. Based on the evidence from all studies including RCTs, WHO issued a consensus statement reiterating the justification of the current policy of preventive chemotherapy.44 Providing deworming to infected populations reflects equity and ethical aspects and the intervention is recognized to reinforce the trust in the health and education service aspects which the Cochrane systematic review of RCTs is unable to evaluate.
 
Progress towards Road map Goals

Progress on specific diseases-e examples of success and challenges. 
Significant progress towards WHO Roadmap Goals and Regional Targets since 2010 has been achieved. The Uniting to Combat NTDs initiative tracks progress on 10 NTDs towards the agreed targets against a scorecard published annually.46 

Dracunculiasis
The Guinea Worm Eradication Programme has, sSince 2010, several six previously endemic countries have been certified free of Guinea Worm transmission (Burkina Faso, Cote d’Ivoire, Ghana, Niger, Nigeria and Togo) including the two previously most endemic countries Nigeria and Ghana. However, four countries remain endemic, Chad, Ethiopia, Mali and South Sudan, who reported only 22 cases in 2015 compared with 126 in 2014.47 Each of these countries pose different challenges if transmission cessation is to be confirmed. In Chad the discovery of a cycle of transmission which involves dogs and fish as paratenic hosts requires a change in approach as 496 503 dog infections were recorded in Chad in 2015.; from January to April 2016 286 dogs have been reported infected aand at least one human case has been confirmed in Chad. No human cases have been reported in other endemic countries to April 2016 .47-48 In Mali access to endemic areas is curtailed due to insecurity and in Gambella region in Ethiopia, both human and dog cases were reported in 2015. In South Sudan significant progress has been made in reducing the numbers of infected villages but problems of access, population movement, cattle camps and insecurity pose end-game challenges. 

Human Trypansomiases
The target to reduce the number of cases of chronic HAT (cHAT) to between 2-3000 per year by 2015 is close to beinghas been achieved as  
WHO reported 3,796 in 2014 and less than 3000 cases in 2015. This was the lowest reported incidence for 75 years achieved by active surveillance of defined high risk foci and availability of the donated products for cHAT therapy-pentamidine and nifurtimox-eflornithine.49 The availability of tiny insecticide impregnated targets for Glossina control,50 new diagnostic tests and the prospect of an oral therapy to treat both phases of the disease-fexnidazole (now in Phase I and III trials)-provide for optimism.  

Chemotherapy for Chagas’ disease remains problematic with <1% of patients accessing benznidazole whilst a randomized trial of benznidazole but did not significantly reduce cardiac clinical deterioration through 5 years of follow-up despite an impact on parasite serological parameters.51 

Leprosy
Reported figures from 103 countries show the global registered prevalence of leprosy to be 180,618 at the end of 2013; during the same year, 215,656 new cases were reported. Over the past 20 years, more than 14 million leprosy patients have been cured, 4 million since 2000. The prevalence of the disease has dropped by 90%: from 21.1 per 10,000 persons to less than 1 per 10,000 persons in 2000. A significant decrease in the global disease burden from 5.2 million in 1985 to 180,618 cases at the end of 2013 has been achieved. However, pockets of high endemicity remain in several countries-India, Brazil, and Indonesia. Whilst the public health problem of leprosy has been reduced, hence the suggestion that the public health problem has been eliminated, despite the value ofby multidrug therapy  elimination of these substantial pockets of disease with drugs donated since 1995 requires this ancient and stigmatising disease toto remains a priority.52

Lymphatic filariasis
In 2014, 73 countries remain endemic but 18 countries are now entering the surveillance phase but yet 11 countries have not yet commenced MDA programmes. Some 23 countries have only implemented limited MDA and have not reached 100% geographic coverage. Countries which have not achieved such coverage will not be unable to reach the 2020 target of elimination. However, some 17 countries have moved into a surveillance phase following Transmission Assessment Surveys, an evaluation which suggests transmission has been arrested.53 However, The Gambia, without the introduction of MDA, appears to have eliminated transmission as a result of the long-term use of impregnated bednets for malaria control.54 A recent estimate of the impact of MDA during the past 13 years suggests >96.71 million cases were prevented or cured yet some 36 million cases of hydrocoele and lymphoedema remain.55 The economic benefits estimated to have accrued during the first 8 years exceed US$ 24 billion. In 2014 some 559 million people were treated and to date the cumulative number of treatments reported was 5.62 billion to over 1 billion individuals.53

An improved method for use in mapping and evaluation based on the immune-chromatographic test has been introduced-the filariasis test strip.56 This test will be used for Transmission Assessment Surveys (TAS) to determine the impact of MDA and allow for decision-making regarding the cessation of MDA or to evaluate any recrudescence post MDA.    LF accounts for at least 2.8 million DALYs;17 this does not include significant co-morbidity of mental illness commonly experienced by patients and their caregiv​ers.20 For GPELF to succeed in eliminating LF as a public health problem, achieving 100% geographical coverage of both MDA and patient care is necessary through the implementation of morbidity management and surgery.53

Onchocerciasis
Three countries have been verified as free of transmission of Onchocerca volvulus-Colombia, Ecuador and Mexico whilst Guatemala has submitted a dossier which indicates that transmission has stopped in all the previous endemic foci, whilst the northern focus in Venezuela is under post control surveillance. However, the cross-border focus straddling Brazil and Venezuela exemplifies challenges of remote areas as migratory Yanomami groups requiring treatment characterise the difficulties of sustaining ivermectin distribution four times/year.  Some individuals who remain positive have been “hospitalized” for treatment with the macrofilaricide doxycycline as a macrofilaricide. 57

The closure of the African Programme for Onchocerciasis Control (APOC) at the end of 2015 and the creation of the Expanded Special Project for the Elimination of NTDs in Africa (ESPEN) for the control of other Preventive Chemotherapy targeted NTDs will transfer the responsibility to the WHO Regional Office for Africa to provide technical support to country programmes. The achievements of APOC include over 1 billion treatments delivered between 1997 and 2014 in 19 countries, capacity building through the training or retraining of over 148,000 health workers and 1.46 million Community Directed Distributors, and the usage of community structures for other health programmes and the empowerment of over 190,000 communities to direct their own ivermectin treatment schedules.58    

From the perspective of epidemiological impact of the programme progress has been made towards nationwide elimination in Burundi, Chad, Guinea Bissau, Kenya, Malawi, Mali, Niger, and Senegal. Focal elimination in 6 countries (Cameroon, Ethiopia, Nigeria, Sudan, Tanzania, Uganda) has been achieved but in Cameroon there are difficulties in high transmission zones, co-endemic with Loa loa, where coverage and adherence are inadequate to satisfy the expectation that transmission can be arrested without additional strategies being implemented.58 

Scabies
Caused by the ecto-parasitic mite, Sarcoptes scabei, is highly susceptible to ivermectin, used in onchocerciasis and lymphatic filariasis programmes. A recent study in Fiji has demonstrated the efficacy of ivermectin for scabies compared with standard treatments of topical permethrin cream. The lack of data on the impact of ivermectin on scabies after nearly three decades of use in MDA programmes is a major deficit which represents an opportunity missed. 59 

Schistosomiasis
The World Health Assembly resolution of 2012 (WHA 65.21)60 called for the elimination of schistosomiasis reinforcing the importance of regular treatment of at least 75% of school age children in areas at risk of both schistosomiasis and soil-transmitted helminthiasis as stated in a previous resolution (WHA 54.19).61 Schistosomiasis programmes will now benefit from the increased donation of praziquantel, as from 2016 250 million tablets equivalent of some 100 million treatments will be available. The numbers of people reported treated in Africa was only some 47.3 million in 2013 compared with over 200 million of those in need in sub Saharan Africa. Scale up remains slow in the highest burden countries where 70% of the burden occurs.46 If the elimination goals for schistosomiasis are to be met endemic countries must define high priority intervention areas, access the available donated drug, implement health education messages to emphasise importance of safe water and sanitation provision in reducing transmission is recognized and recognize the importance of pre-school age children and their need for treatment if possible with a paediatric formulation of praziquantel.62 The inter-relation between HIV and urogenital schistosomiasis requires resolution with strong policy enforcement through the regular treatment of school-girls and women of child bearing age and also during pregnancy or lactation as recommended by WHO and the original manufacturers of praziquantel.22

Soil Transmitted Helminthiases (STH)
Between 2008 and 2013 the number of children treated for STH doubled and in 2014 WHO reported that 440 million pre school and school age children were treated with the anthelminthics-albendazole and mebendazole-with a global coverage of between 44 and 51 % of those in need of treatment with rates of coverage increasing since 2008.6,63 The STH figures do not include those receiving anthelminthics via filariasis and onchocerciasis programmes which treat adults population as well as the younger age groups.31 The need to treat adults if a permanent reduction in transmission is to be achieved is recognized64 as well as the importance of the role of the WASH sector in sustaining the gains regular deworming can provide.65  

Trachoma
The SAFE strategy for the elimination of trachoma with its four components (Surgery, Antibiotics, Face washing and Environment) demonstrates the multiple approaches required if public health goals are to be achieved.46 The GTMP has provided the detailed information required to embark on MDA using azithromycin, identified where the burden of trichiasis is highest to prioritise surgery and where implementation of the F and E components will pose the greatest challenge.36 The implementation of MDA in all endemic districts at 80% coverage for 3-5 years, depending on prevalence of active trachoma, will pose a significant challenge notwithstanding the estimated backlog of 5 million cases of trichiasis surgery. However, a recent study has emphasised the benefit of improved trichiasis surgery technique in reducing  theits recurrence.66
    
Yaws
Yaws (Treponema pallidum pertenue) the disabling skin condition has been identified as an eradication target based on the impact of oral azithromycin. WHO developed the Morges Strategy for Yaws Eradication by 2020 based on MDA of single dose azithromycin to entire endemic communities supported by surveillance until clinical cases are no longer detected and by treatment of all active cases and their contacts.67 Pilot interventions have been initiated in several countries whilst in Nsukka, Nigeria MDA using oral azithromycin interrupted transmission within 6-12 months. India, following a long campaign using penicillin injection as a strategy, followed by sero-surveillance of children for treponemal antibodies has reported that yaws transmission has been achieved and declared “eradication”- technically elimination.68

Implementation strategies requiring collaboration with other sectors.

Vector control
Vector control has been a major component of NTD programmes over many decades. A number of NTDs such as lymphatic filariasis, visceral leishmaniasis, onchocerciasis  and Chagas’ disease have benefitted from  vector control.69 In addition new approaches to the control of human African sleeping sickness using the tiny target  technology50 or selective spraying of cattle for control of the acute zoonotic form of disease have shown to be effective interventions but require implementation at scale.70 There is a significant neglected vector control agenda - as the development of novel tools and methods to curb the spread of (day- and outdoor- biting) Aedes mosquitos transmitting dengue71 and Chikungunya72 are a high priority reinforced by the emergence of Zika virus.    This will require significant increased investment, if vector control strategies involving new products are to be implemented.6 The threat of increasing resistance to current pyrethoid based insecticides could inhibit the progress of the filariasis elimination programme in Africa.42 Global warming, climate change, unplanned urbanisation and global travel of people and goods will have an impact beyond the traditional populations associated with NTDs. The establishment of schistosomiasis in Corsica exemplifies these threats- the existence of susceptible snail populations and their ability to become infected with a parasite strain from Africa, a hybrid of Schistosoma haematobium and S. bovis, with the potential of these strainsto becominge established in southern Europe.73

Neglected Zoonotic Diseases: the One Health concept
Neglected zoonotic diseases occur in a diversity ofmany settings, caused by diverse groups of organisms hence generalisations about approaches to their control is difficult. However, progress has been made in defining the strategies for control of specific diseases which require an approach which goes beyond the health sector.74 The vision for One Health is a culture change that recognises the importance of the link between humans, animals and ecosystems providing added value by translating the One Health approach into zoonotic disease control. Successful application of One Health strategies are the use of dog vaccination in the control of human rabies in Latin America, Kwa Zulu Natal, the Philippines and Bali75 and the control of the acute form of human sleeping sickness, Trypansoma brucei rhodesiense in South East Uganda.   In Uganda chemotherapy of the cattle reservoir, together with vector control by spraying cattle to selectively kill the tsetse fly Glossina fuscipes, has been shown effective in reducing the incidence of sleeping sickness cases.70 The One Health approach can also be applied to control of cysticercosis and echinococcosis, globally distributed cestode infections, where interventions focussed on on the animal reservoirs (pigs and dogs) are essential components of a control strategyinterventions to reduce human prevalence allied to behaviour change and curative therapy.76,77

WASH
Sustained control and elimination of soil transmitted helminthiases and schistosomiasis, require not only chemotherapy but also access to clean and safe water together with appropriate waste disposal and behaviour change essential if transmission is to be reduced. However, to effect provision of clean and safe water in the more remote areas where NTDs as well as other water borne infections are most prevalent poses a significant challenge and crucially depends on the involvement other sectors.  The engagement of the WASH sector and the inclusion of NTDs within the WASH framework reflects a holistic policy approach within the SDG goals.65

Place of NTDs in the Global Health context towards 2030

Conclusions
 	Over the last decade NTDs have attracted increased attention and investment. The availability of drugs is no longer a barrier to achieving universal coverage for most NTDs yet they remain a “chronic pandemic” in the poorest sectors of society in endemic countries who now have access to donated drugs. Further progress will be driven by countries committing to contribute to the relatively small costs of delivery estimated at 1-3% of national health budgets to ensure access-donated products with a calculated annual value of US$ 2-3 billion. In 20145 some one 1.1 billion people received preventive chemotherapy which represents a public health success46 ;and  270 million children were dewormed in a single day in February 2016 in India.78 However, progress towards achieving the 2020 WHO Roadmap targets has been patchy. The resources allocated to NTDs are not yet adequate to address the totality of the problem and the funding gap of around US$ 200-300 million needs excluding that required for vector control.6 The challenge is to persuade endemic countries to invest national resources to develop robust and dependable health delivery systems to ensure the gains from NTD control/ elimination are translated into long term human development gains.
NTDs are tracers of equity in progress toward other Sustainable Development Goals and targets.15 This includes universal health coverage (target 3.8), access to safe water (target 6.1), and sanitation (target 6.2), . NTD endemic populations are the least likely to have access to these services hence using NTDs as an indicator of progress is a logical step to justify these diseases in the SDGs targets.  Other SDG goals upon which NTD interventions and partnerships are relevant are education (target 4), gender equality (target 5), decent work and economic growth (target 8), reduced inequalities (target 10), sustainable cities and communities (target 11), climate action (target 13) and partnership for the goals (target 17) . The most recent WHO / World Bank report on monitoring Universaal Health Coverage is explicit “monitoring preventive chemotherapy remains key to ensuring that the diseases of the least well- off are being prioritised from the very beginning of the path to UHC”.79
However, there are additional challenges with respect to implementation as well as the need for a new generation of products; countries have limited human resources; some populations are difficult to access; civil unrest and conflict impede implementation;80 there is potential for development of drug resistance and insecticide resistance whilst environmental change impacts on the ecology and behaviour of vectors.42  In addition the value of quantitative and mathematical modelling approaches to inform policy decisions for a group of NTDs has been emphasised through the work of the NTD Modelling Consortium.81 Studies on  the health gains from NTD programmes have estimated that 175 million DALYs have been averted in the 15 years of the lymphatic filariasis programme 82 , whilst if targets are met for nine NTDs 600 million DALYs would be averted extrapolated to 2030 largely due to the decline in morbidity of NTDs treated by preventive chemotherapy 83. However, this figure does not estimate for gains in subtle morbidities through improved  cognitive development and mental health and only nine NTDs were used in the calculation. This suggests that overall from all NTD programmes would be substantially greater than the 600 million DALY figure. 
The stated commitments of donors should be translated into resources to redress the inequities of financing which NTD programmes currently suffer and give the poor what they deserve: access to free, high quality effective products as they continue to be exposed to an avoidable “chronic pandemic” which claimed at least 10 times more lives than the Ebola epidemic in a single year. 
Contribution
DHM wrote the first draft and took the lead role in developing the paper; LS and DE contributed to further development of the content and structure of the paper in particular the policy elements, editing and agreeing to the final version.
Conflicts of Interest
DHM receives support from the UK Department for International Development Development as part of the COUNTDOWN NTD Implementation Research award to the Liverpool School of Tropical Medicine and GlaxoSmithKline (GSK). LS is the Chair of the Executive Group of the Global Schistosomiasis Alliance; DE declares he has no Conflict of Interest.
Acknowledgements
We are most grateful to Drs Mark Bradley (GSK), Antonio Montresor (WHO) and Adrian Hopkins (Mectizan Donation Program) for constructive and helpful comments and Joan Fahy for her assistance in organising the manuscript.

REFERENCES

1.	Liese B, Rosenberg M, Schratz A. Programmes, partnerships, and governance for elimination and control of neglected tropical diseases. Lancet 2010; 375: 67-76.
2.	Gyapong JO, Gyapong M, Yellu N, et al. Integration of neglected tropical diseases into health care challenges and opportunities. Lancet 2010; 375:1-6.
3.	Baker MC, Mathieu E, Fleming FM, et al. Mapping, monitoring, and surveillance of neglected tropical diseases: towards a policy framework. Lancet 2010; 375: 231-238.
4.	Conteh L, Engels T, Molyneux DH.  Socioeconomic aspects of neglected tropical diseases. Lancet 2010; 375: 239-247.
5.	Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009;373:1570-5.
6.	World Health Organization. Investing to overcome the global impact of neglected tropical diseases: WHO third report on neglected tropical diseases: https://www.yumpu.com/en/document/view/37074971/1a9bnbk/5; 2015.
7.	Liese BL, Houghton N, and Teplitskaya L. Development assistance for neglected tropical diseases: progress since 2009. Int Health 2014; 6: 162-171. 
8.	London Declaration on Neglected Tropical ~Diseases. Uniting to Combat NTDs.  http://unitingtocombatntds.org/sites/default/files/document/london_declaration_on_ntds.pdf (​http:​/​​/​unitingtocombatntds.org​/​sites​/​default​/​files​/​document​/​london_declaration_on_ntds.pdf​)
9.	World Health Assembly. Neglected tropical diseases Prevention, control, elimination and eradication. World Health Assembly 2013: 66:12.
10.	World Health Organization. A Roadmap for Implementation: Accelerating work to overcome the global impact of neglected tropical diseases 2012. http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf (​http:​/​​/​www.who.int​/​neglected_diseases​/​NTD_RoadMap_2012_Fullversion.pdf​) 
11.	United Nations. A new global partnership: eradicate poverty and transform economies through sustainable development. The Report of the High-Level Panel of Eminent Persons on the Post-2015 Development Agenda.  United Nations Publications. 2013; 300 E 42nd Street, New York, NY 10017.
12.	The Global Fund. Sustainable development goal document UN 33rd Meeting of the Board of the Global Fund Framework for financing co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria. http://www.theglobalfund.org/en/board/decisions/ (​http:​/​​/​www.theglobalfund.org​/​en​/​board​/​decisions​/​​); 
13.	G7 Germany. Schloss Elmau.  2015. https://www.g7germany.de/Content/DE/_Anlagen/G8_G20/2015-06-08-g7-abschluss-eng.pdf?__blob=publicationFile&v=5 (​https:​/​​/​www.g7germany.de​/​Content​/​DE​/​_Anlagen​/​G8_G20​/​2015-06-08-g7-abschluss-eng.pdf?__blob=publicationFile&v=5​)
14.	Hotez PJ. Blue Marble Health Redux: Neglected Tropical Diseases and Human Development in the Group of 20 (G20) Nations and Nigeria. PLoS Negl Trop Dis 2015; 8: e0004035.
15.	Engels D.  Neglected tropical diseases in the Sustainable Development Goals Lancet 2016; 387: 223-234.
16.	Cross C, Olamiju F, Richards F, Bush S, Hopkins A, Haddad D. Historical Profiles and Perspectives From River Blindness to Neglected Tropical Diseases – Lessons Learned in Africa for Programme Implementation and Expansion by the Non-governmental Partners. PLoS Negl Trop Dis 2015; 10:371.
17.	Murray CJ, Vos T, Lozano R, Naghavi M, et al. Disability-Adjusted Life Years (Dalys) for 291 Diseases and Injuries in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010. Lancet 2012: 380 ;2197-2223.
18.	Hotez PJ, Alvarado M, Basáñez M-G, et al. The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases. PLoS Negl Trop Dis 2014; 7: e 2865.
19.	King CH, Bertino AM.  Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases.  PLoS Negl Trop Dis 2008; 2: e209. 
20.	Ton T, Mackenzie CD, Molyneux DH. The Burden of Mental Health in Lymphatic Filariasis. Infectious Diseases of Poverty 2015; 30: 4-34.
21.	Ndeffo Mbah ML, Kjetland EF, Atkins KE, et al.  Cost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa.  Proc Natl Acad Sci U S A 2013; 110 :7952-7.
22.	Olveda RM, Acosta LP, Tallo V, Baltazar PI, Lesiguez JLS, Estanislao GG, et al. Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Inf Dis 2016; 16:199-208. 
23.	Bhattarai R, Budke CM, Carabin H, et al. Estimating the non-monetary burden of neurocysticercosis in Mexico. PLoS Negl Trop Dis 2012; 6: e1521. 
24.	Furst T, Keiser J, Utzinger J. Global Burden of food borne trematodiasis: a systematic review and meta analysis. Lancet Inf Dis 2012; 12: 210-221.  
25.	Khaled H. Schistosomiasis and cancer in Egypt: review. J Adv Res (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​25685453" \o "Journal of advanced research.​) 2013;4:4616
26.	http://www.who.int/tdr/publications/year/2012/en/ (​http:​/​​/​www.who.int​/​tdr​/​publications​/​year​/​2012​/​en​/​​)
27.	Hadinegoro SR, Arredondo-García JL, Capeding MR, and the CYD-TDV Dengue Vaccine Working Group.  Efficacy and Long-Term Safety of a Dengue Vaccine in regions of Endemic Disease (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​26214039​). N Engl J Med 2015;373:1195-206. 
28.	Utzinger J, Keiser J Shuhua X, Tanner M, Singer BH.  Combination Chemotherapy of Schistosomiasis in Laboratory Studies and Clinical Trials. Antimicrob Agents Chemother 2003 47:1487-95
29.	Allen T, Parker M.  Will increased funding for neglected tropical diseases really make poverty history? Lancet 2012; 379: 1097-8
30.	Chami GF, Kontoleon A, Bulte E et al. Profiling nonrecipients of mass drug administration for schistosomiasis and hookworm infections: a comprehensive analysis of praziquantel and albendazole coverage in community-directed treatment in Uganda. Clin Inf Dis 2016; 62:200-7.
31.	Molyneux DH, Hopkins A, Bradley MH, Kelly-Hope L. Multidimensional complexities of filariasis control in an era of large-scale mass drug administration programmes: a can of worms. Parasit Vectors 2014; 4: 1756-3305.
32.	Ngoumou P, Walsh JF, Mace JM. A rapid mapping technique for the prevalence and distribution of onchocerciasis: a Cameroon case study.  Ann Trop Med Parasitol 1994; 88: 463-474.
33.	Zouré HG, Wanji S, Noma M, et al. The Geographic Distribution of Loa loa in Africa: Results of Large-Scale Implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis. 2011; 5:e1210
34.	Gyapong JO, Kyelem D,  Kleinschmidt I, et al. The use of spatial analysis in mapping the distribution of bancroftian filariasis in four West African countries. Ann Trop Med Parasitol 2002; 96: 695-705.
35.	NTD Mapping Tool. www.NTDMap.org (​http:​/​​/​www.NTDMap.org​)
36.	Sightsavers. Global Trachoma Mapping Project www.sightsavers.net/our_work/how_we_work/.../18687.html (​http:​/​​/​www.sightsavers.net​/​our_work​/​how_we_work​/​...​/​18687.html​)
37.	Simarro PP, Cecchi G, Franco JR, et al. Estimating and mapping the population at risk of sleeping sickness. PLoS Negl Trop Dis 2012; 6: e1859.
38.	Sime H, Deribe K, Assefa A, et al.  Integrated mapping of lymphatic filariasis and podoconiosis; lessons learnt from Ethiopia. Parasit Vectors 2014; 27; 7-397. 
39.	Global Atlas of Helminth Infections. www.wormyworld.org (​http:​/​​/​www.wormyworld.org​).
40.	World Health Organiztion. Progress towards eliminating onchocerciasis in the WHO Region of the Americas: verification by WHO of elimination of transmission in Colombia. Weekly Epidemiological Record.  2013; 88: 381-388.
41.	Thomsen EK, Sanuku N, Baea M, et al Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. Clin Infect Dis 2016; 62 :334-41.
42.	Hemingway J, Ranson J, Magill A, et al. Averting a malaria disaster: will insecticide resistance derail malaria control?  Lancet 2016 S0140-6736(15)00417-1. doi: 10.1016/S0140-6736(15)00417-1.
43.	Taylor-Robinson DC, Maayan N, Soares-Weiser K, Donegan S, Garner P. Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance. Cochrane Database Syst Rev 2015; 23: 7.
44.	WHO. Advisory body upholds continued deworming of children against soil - transmitted helminthiases. 2015. http://www.who.int/neglected_diseases/news/update-deworming-children/en/cochrane (​http:​/​​/​www.who.int​/​neglected_diseases​/​news​/​update-deworming-children​/​en​/​cochrane​)
45.	Stoltzfus RJ, Chwaya HM, Tielsch J, Schulze KJ, Albonico M, Savioli L. Epidemiology of iron deficiency anaemia in Zanzibari schoolchildren: the importance of hookworms . Am. J Clin Nut 1997; 65:153-159.
46.	Uniting to Combat NTDs. http://unitingtocombatntds.org (​http:​/​​/​unitingtocombatntds.org​) accessed 18 May 2016 Reaching the unreached. Foutrh Progress Report of the London Declaration
47.	Centers for Disease Control. Guinea Worm Wrap-Up No 23840. Jan May 2016. Provisional count for 2015: 22 cases of Guinea Worm disease worldwideChad Reports 2 cases and 286 Infected Dogs in January –April 2016.
48.	Eberhard ML, Ruiz-Tiben E, Hopkins DR, et al. The peculiar epidemiology of Dracunculiasis in Chad. Am J Trop Med Hyg 2013;13: 61-70. 
49.	World Health Organization..  Report of a WHO Expert Committee on Control and surveillance of human African Trypanosomiasis.  Technical Report Series, 2013, No.984 http://apps.who.int/iris/bitstream/10665/95732/1/9789241209847_eng.pdf?ua=1 (​http:​/​​/​apps.who.int​/​iris​/​bitstream​/​10665​/​95732​/​1​/​9789241209847_eng.pdf?ua=1​).
50.	Tirados I, Esterhuizen J, Kovacic V, et al. Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy. PLoS Negl Trop Dis 2015; 12; e0003822. doi: 10.1371/journal.pntd. 0003822. eCollection.
51.	Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy. N Engl J Med 2015; 373:1295-1306.
52.	World Health Organization. Global leprosy: update on the 2012 situation. Weekly Epidemiological Record 2013; 88: 365–380.
53.	World Health Organization. Global Programme to Eliminate Lymphatic Filariasis: Progress Report 2014. Weekly Epidemiological Record, 2015, 90, 489–504.
54.	Rebollo MP, Sambou SM, Thomas B et al.  Elimination of lymphatic filariasis in Gambia.  PLoS Negl Trop Dis. 2015; 18: e0003642.
55.	Ramaiah KD, Ottesen EA. Progress and Impact of 13 Years of the Global Programme to Eliminate Lymphatic Filariasis on Reducing the Burden of Filarial Disease. PLOS Negl Trop Dis 2014; 11  e3319.
56.	Weil G, Curtis KC, Fakoli L, Fischer K, et al. Laboratory and field   evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood. Am J Trop Med Hyg 2013; 89:11-5. 
57.	Rodríguez-Pérez MA (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​?term=Rodr%C3%ADguez-P%C3%A9rez%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=26161558​), Fernández-Santos NA (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​?term=Fern%C3%A1ndez-Santos%20NA%5BAuthor%5D&cauthor=true&cauthor_uid=26161558​), Orozco-Algarra ME (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​?term=Orozco-Algarra%20ME%5BAuthor%5D&cauthor=true&cauthor_uid=26161558​), et al.  Elimination of Onchocerciasis from Mexico.  PLoS Negl Trop Dis. 2015;9:e0003922. doi: 10.1371/journal.pntd. 0003922. eCollection 2015.
58.	Roungou JB, Yameogo L, Mwikisa C, Boakye DA, Bundy A.  40 Years of the APOC Partnership.  PLOS Negl Trop Dis 2015; | DOI:10.1371/journal.pntd.0003562.
59.	Romani L, Whitfeld MJ, Koroivueta J, et al.  Mass Drug Administration for Scabies in a Population with Endemic Disease. Engl J Med. 2015; 373:2305-13.
60.	World Health Organization. World Health Assembly Resolution WHA 65.21 Elimination of schistosomiasis. 2012 http://www.who.int/neglected_diseases/mediacentre/WHA_65.21_Eng.pdf (​http:​/​​/​www.who.int​/​neglected_diseases​/​mediacentre​/​WHA_65.21_Eng.pdf​).
61.	World Health Organization. World Health Assembly Resolution WHA 54.19 Elimination of schistosomiasis. 2001 http://www.who.int/neglected_diseases/mediacentre/WHA_54.19_Eng.pdf (​http:​/​​/​www.who.int​/​neglected_diseases​/​mediacentre​/​WHA_54.19_Eng.pdf​).
62.	Trastullo R, Dolci LS, Passerini N, Albertini B. Development of flexible and dispersible oral formulations containing praziquantel for potential schistosomiasis treatment of pre-school age children.   Int J Pharm. 2015; 495, 536-50. 
63.	World Health Organization. Schistosomiasis: number of people receiving preventive chemotherapy in 2012. Weekly Epidemiological Record 2014; 89: 21-28.   
64.	Anderson RM, Turner HC, Truscott JE, Hollingsworth TD, Brooker SJ.  Should the Goal for the Treatment of Soil Transmitted Helminth (STH) Infections Be Changed from Morbidity Control in Children to Community-Wide Transmission Elimination? PLoS Negl Trop Dis. 2015; 9 :e0003897. doi: 10.1371/ journal.pntd.0003897. eCollection 2015 Aug. 
65.	World Health Organization. Water Sanitation & Hygiene for accelerating and sustaining progress on Neglected Tropical Diseases – a global strategy 2015-2020. Geneva: World Health; 2015 http://apps.who.int/iris/bitstream/10665/182735/1/WHO_FWC_WSH_15.12_eng.pdf?ua=1 (​http:​/​​/​apps.who.int​/​iris​/​bitstream​/​10665​/​182735​/​1​/​WHO_FWC_WSH_15.12_eng.pdf?ua=1" \t "_blank​).
66.	Solomon A. Optimising the management of trachomatous trichiasis Lancet Glob Health 2016 pii: S2214-109X(16)00004-8. doi: 10.1016/S2214-109X(16)00004-8.
67.	Marks M, Mitjà O, Vestergaard LS, et al.  Challenges and key research questions for yaws eradication.  Lancet Infect Dis. 2015;15:1220-5. doi: 10.1016/S1473-3099(15)00136-X. 
68.	World Health Organization. Eradication of yaws in India. Weekly Epidemiological Record, 2015; 90: 161-168.
69.	Molyneux DH. ‘Neglected’ diseases but unrecognised successes – challenges and opportunities for infectious disease control.  Lancet 2004; 364: 380-3.
70.	Welburn SC, Beange I, Ducrotoy MJ, Okello AL.  The neglected zoonoses-the case for integrated control and advocacy.  Clin Microbiol Infect. 2015; 21:433-443. 
71.	Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013; 4496: 504-507. 
72.	World Health Organization. Chikungunya. Fact Sheet No 327; 2015 http://www.who.int/mediacentre/factsheets/fs327/en/ (​http:​/​​/​www.who.int​/​mediacentre​/​factsheets​/​fs327​/​en​/​​)
73.	Boissier J, Moné H, Mitta G, et al. Schistosomiasis reaches Europe. Lancet Infect Dis 2015; 15, 757-8.
74.	Molyneux D, Hallaj Z, Keusch GT, et al.  Zoonoses and mariginalised infectious diseases of poverty: where do we stand? Parasit Vectors. 2011; 14: 4-106.
75.	World Health Organization.  WHO Expert Consultation on rabies. Second report. WHO Tech Rep Ser. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​24069724" \o "World Health Organization technical report series.​)2013; 982: 1-139
76.	Lightowlers MW. Control of Taenia solium taeniasis/cysticercosis: past practices and new possibilities. Parasitology 2013;140:1566-77. 
77.	Mewara A, Goyal K, Sehgal R. Neurocysticercosis: A disease of neglect. Trop Parasitol 2013, 3,106-13. 
78.	World Health Organization.  World’s largest deworming campaign targets 270 million children in one day. WHO 2016 http://www.who.int/neglected_diseases/news/270_million_children_treated_in_one_day/en/ (​http:​/​​/​www.who.int​/​neglected_diseases​/​news​/​270_million_children_treated_in_one_day​/​en​/​​)
79.	World Health Organization, World Bank. Tracking Universal Health Coverage: the first global monitoring report 2015. http://apps.who.int/iris/bitstream/10665/174536/1/978924156977 (​http:​/​​/​apps.who.int​/​iris​/​bitstream​/​10665​/​174536​/​1​/​978924156977​) eng pdf
80.	Webster JP, Molyneux D, Hotez PJ Fenwick A. The contribution of mass drug administration to global health – past, present and future. Philos Trans R Soc Lond B Biol Sci 2014; 201: 30434
81.	Hollingsworth (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​?term=Hollingsworth%20TD%5Bauth%5D​) TD, Adams (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​?term=Adams%20ER%5Bauth%5D​) EA, Anderson (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​?term=Anderson%20RM%5Bauth%5D​) RA, and the NTD Modelling Consortium.  Quantitative analyses and modelling to support achievement of the 2020 goals for nine neglected tropical diseases. Parasit Vectors 2015; 8: 630.10.1186/s13071-015-1235-1 (​http:​/​​/​dx.doi.org​/​10.1186%2Fs13071-015-1235-1​) PMCID: PMC4674954
82.	Turner HC, Bettis AA, Chu BK, et al The health and economic benefits of the the Global programme toEliminate Lymphatic Filariasis (2000-2014) Inf Dis Pov. 2016
83.	de Vlas SJ, Stolk, WA, le Rutte, EA et al. Cocerted efforts to Control or Eliminat Neglected Tropical Diseases: How much health will be gained ? PLoS Negl Trop Dis 2016 10, e 000386





2



